Status:
ENROLLING_BY_INVITATION
PDE3B in Metabolic Regulation
Lead Sponsor:
Cambridge University Hospitals NHS Foundation Trust
Collaborating Sponsors:
University of Cambridge
Conditions:
Type 2 Diabetes
Cardiometabolic Syndrome
Eligibility:
All Genders
21-75 years
Brief Summary
Phosphodiesterase 3B (PDE3B), an enzyme responsible for the degradation of cyclic AMP and GMP (two important second messengers used for intracellular signal transduction), has been associated with car...
Detailed Description
Phosphodiesterase 3B (PDE3B) is a protein that plays a role in how cells handle nutrients (i.e. glucose and fats). The investigators have recently found that people who have a gene variant (i.e., chan...
Eligibility Criteria
Inclusion
- willing and able to give informed consent for participation in the study
- aged 21-75 years
- men and women
Exclusion
- unstable weight (\>5% change the last 2 months)
- type 2 diabetes or other major organ dysfunction
- cancer in last 5 years
- gastrointestinal or bariatric surgery (except cholecystectomy and appendectomy)
- conditions that render subject unable to complete all testing procedures (including individuals with known allergies or contraindications to the medications used in this study)
- use of medications that affect the study outcome measures or increase the risk of study procedures and that cannot be temporarily discontinued
- smoking
- illegal drug use
- pregnant or lactating
- unable to grant voluntary informed consent or comply with the study instructions
Key Trial Info
Start Date :
September 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2029
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06533007
Start Date
September 1 2025
End Date
September 1 2029
Last Update
November 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cambridge University Hospital
Cambridge, United Kingdom, CB2 0QQ